- Investing.com
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, and Overseas. It operates m3.com, a members-only web site for providing information to the healthcare professionals; MR-kun, where member doctors can independently and continuously receive information on the m3com platform; QOL-kun that provides life support information other than medical information to members; AskDoctors, where registered doctors answer questions about health and illness from the general public; MDLinx for medical professionals in the United States; and Doctors.net.uk, a website that provides developing services for pharmaceutical companies, as well as provides drug information database in France, Germany, and Spain. The company also provides career services for doctors and pharmacists, recruitment, and posting job advertisements through m3.com CAREER. In addition, it engages in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; survey service for medical professionals; sale and marketing support businesses for pharmaceutical companies, etc. through the Internet; provision of management support and consulting services to medical institutions, and home-visit nursing services; and provision of human resources services for healthcare professionals, as well as operates clinical trial facilities. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
Metrics to compare | 2413 | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship Relationship2413PeersSector | |
---|---|---|---|---|
P/E Ratio | 24.6x | 18.9x | −0.6x | |
PEG Ratio | −1.28 | 0.42 | 0.00 | |
Price/Book | 2.8x | 2.6x | 2.6x | |
Price / LTM Sales | 3.9x | 3.1x | 3.3x | |
Upside (Analyst Target) | 20.0% | 31.0% | 45.3% | |
Fair Value Upside | Unlock | 31.7% | 6.1% | Unlock |